Shots:

• Takeda will screen & optimize compounds derived from Debiopharm's Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders
• Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program. The candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the natural balance of the microbiota
• The collaboration allows Debiopharm to boost its microbiome remodeling program. Additionally- Debiopharm has significantly expanded its antibiotic and microbiology pipeline with the launch of several discovery programs and initiates P-II study in bone and joint infections with afabicin (Debio 1450)

Click here to read full press release/ article 

Ref: PRNewswire | Image: Takeda